{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-046765","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2022-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.659200+00:00","generated_at":"2026-06-27T06:41:35.639812+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"CEO Tillman Gerngross resigns; COO David Hering to serve as Interim CEO","bullets":["CEO Tillman Gerngross agreed in principle to resign effective February 14, 2022.","COO David Hering appointed as Interim CEO; details to follow in subsequent filings.","Company intends to issue a press release with further management transition details."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-046765","json":"https://secwatch.observer/filing/0001193125-22-046765.json","markdown":"https://secwatch.observer/filing/0001193125-22-046765.md","text":"https://secwatch.observer/filing/0001193125-22-046765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522046765/0001193125-22-046765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522046765/d290085d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:41:35.639812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12b087cb49","claim":"Tillman Gerngross resigned as Chief Executive Officer at Invivyd, Inc..","evidence_excerpt":"On February 14, 2022, Tillman Gerngross, Ph.D. communicated to the Chairperson of the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) that he agreed in principle to resign from his position as Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522046765/0001193125-22-046765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"affc51f8e8","claim":"David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..","evidence_excerpt":"The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company’s Chief Operating Officer) as Interim Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832038/000119312522046765/0001193125-22-046765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}